Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has 8 years of Operating Leases data on file, last reported at $218.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 5.23% year-over-year to $218.0 million; the trailing twelve-month figure through Mar 2026 stood at $218.0 million (down 5.23% YoY), and the FY2025 full-year result was $225.1 million, down 1.94% from the prior year.
• Operating Leases for Q1 2026 stood at $218.0 million, down from $225.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $277.4 million in Q1 2022 and bottomed at $218.0 million in Q1 2026.
• The 5-year median for Operating Leases is $239.4 million (2024), against an average of $243.8 million.
• The widest annual swing landed in 2024, when Operating Leases slipped 8.32%; it then decreased 1.94% in 2025.
• A 5-year view of Operating Leases shows it stood at $261.3 million in 2022, then retreated by 6.98% to $243.1 million in 2023, then decreased by 5.58% to $229.5 million in 2024, then retreated by 1.94% to $225.1 million in 2025, then slipped by 3.14% to $218.0 million in 2026.
• The last three Operating Leases figures came in at $218.0 million (Q1 2026), $225.1 million (Q4 2025), and $223.4 million (Q3 2025), per Business Quant data.

Peer Comparison